News & Events
Wednesday, February 17, 2010
Soligenix Announces Issuance of Hong Kong Patent for its LPM™ Oral Drug Delivery Technology
[read more]Wednesday, February 03, 2010
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 02, 2010
Soligenix Announces Publication of Positive Stability Results with RiVax™, its Vaccine Against Ricin Toxin
Preclinical Data Demonstrate the Potential for Long-term Stability of RiVax™ [read more]Monday, December 28, 2009
Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax™, its Vaccine Against Ricin Toxin
Collaborative Effort Between Soligenix and Wadsworth Center Describes the Properties of Protective Antibodies to Ricin Toxin
[read more]Monday, December 21, 2009
Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201
for the Prevention of Acute Radiation Enteritis
[read more]Friday, November 20, 2009
Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax™ and Other Rapidly Acting Vaccines
[read more]Friday, November 13, 2009
Soligenix Reports Third Quarter 2009 Financial Results
[read more]Tuesday, October 27, 2009
Soligenix to Present at 8th Annual BIO Investor Forum
Presentation at 1PM PDT, Thursday, October 29, Available by Webcast
[read more]Wednesday, October 21, 2009
Soligenix to Provide Corporate Update
[read more]Thursday, October 15, 2009
Soligenix Announces Initiation of its Confirmatory Phase 3 Clinical Trial of orBec® in Acute GI GVHD
[read more]Friday, October 09, 2009
Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
[read more]Wednesday, September 30, 2009
DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol “SNGX”
[read more]Thursday, September 24, 2009
DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
[read more]Monday, September 21, 2009
DOR BioPharma Announces $9.4 Million NIH Grant Award to
Develop Thermostable and Rapidly Acting Vaccines
[read more]Tuesday, September 08, 2009
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
[read more]Thursday, September 03, 2009
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference,
Presentation to be Webcast Live
[read more]Friday, August 14, 2009
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
[read more]Tuesday, August 04, 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec® for the Treatment of Chronic Gastrointestinal GVHD
[read more]Wednesday, July 08, 2009
DOR BioPharma Announces Issuance of European Patent for its LPM™ Oral Drug Delivery Technology
[read more]Tuesday, July 07, 2009
DOR BioPharma Announces Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
[read more]Monday, June 29, 2009
DOR BioPharma Announces Publication of orBec® Clinical Pulmonary Data in Bone Marrow Transplantation
[read more]Tuesday, June 09, 2009
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
[read more]Friday, May 15, 2009
DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
[read more]Tuesday, March 31, 2009
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
[read more]Wednesday, March 25, 2009
DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement with Numoda Corporation
[read more]Monday, March 16, 2009
DOR BioPharma Appoints Gregg Lapointe, CPA, MBA,
to its Board of Directors
[read more]Friday, March 13, 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD, as Chief Medical Officer
[read more]Thursday, February 12, 2009
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec® in the Treatment of Graft-versus-Host Disease
[read more]Tuesday, January 27, 2009
DOR BioPharma Announces Appointment of Christopher J. Schaber, PhD, to BioNJ Board of Directors
[read more]Monday, January 26, 2009
DOR BioPharma Announces Formation of Acute Radiation Enteritis Medical Advisory Board
[read more]Tuesday, January 20, 2009
DOR BioPharma Announces Engagement of Amper, Politziner & Mattia, LLP as New Auditors
[read more]Monday, January 12, 2009
DOR BioPharma Announces Private Equity Financing of $2.28 Million with Single Institutional Investor
[read more]Tuesday, January 06, 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
[read more]Monday, January 05, 2009
DOR BioPharma Receives SPA Clearance from the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
[read more]Monday, December 08, 2008
DOR BioPharma Announces FDA Clearance of IND for DOR201 in Radiation Enteritis
[read more]Monday, December 01, 2008
DOR BioPharma Receives $1.5 Million from Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec® Strategic Alliance
[read more]Tuesday, November 18, 2008
DOR BioPharma's orBec® Receives Orphan Drug Designation in Australia for the Treatment of GI GVHD
[read more]Friday, November 14, 2008
DOR BioPharma Reports 3rd Quarter 2008 Financial Results, DOR Begins Generating Revenue from Named Patient Sales of orBec®
[read more]Monday, November 10, 2008
DOR BioPharma Receives Guidance from FDA on Proposed Confirmatory Phase 3 Clinical Trial Design of orBec® in GI GVHD
[read more]Friday, November 07, 2008
DOR BioPharma to Present at the Biotech 2008 Conference, Regional Conference to Highlight Innovative Biotech Companies
[read more]Wednesday, November 05, 2008
DOR BioPharma to Present at the Rodman & Renshaw 10th Annual Investor Healthcare Conference, Presentation to be Webcast Live
[read more]Thursday, October 30, 2008
DOR BioPharma Announces Expansion of Named Patient Access Collaboration with BurnsAdler into Canada, DOR Begins Booking Sales Pursuant to its Named Patient Programs
[read more]Wednesday, September 17, 2008
DOR BioPharma Forms orBec® European Medical Advisory Board
[read more]Monday, September 15, 2008
DOR BioPharma Announces Second orBec® Clinical Summary Published in Expert Opinion on Investigational Drugs
[read more]Wednesday, September 10, 2008
DOR BioPharma Announces Named Patient Access Program for Latin America in Collaboration with BurnsAdler, orBec® Positioned to be Available under Named Patient Programs in over 50 Countries Worldwide
[read more]Wednesday, August 27, 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in Thailand and Other ASEAN Countries in Collaboration with Pacific Healthcare
[read more]Friday, August 15, 2008
DOR BioPharma Reports 2nd Quarter 2008 Financial Results
[read more]Thursday, August 07, 2008
DOR BioPharma Announces Initiation of Second Human Clinical Trial for RiVax™, its Ricin Toxin Vaccine
[read more]Friday, July 18, 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in Singapore and Malaysia in Collaboration with Steward Cross Pte Ltd
[read more]Tuesday, July 15, 2008
DOR BioPharma Enters into Collaborative Agreement with IDIS for Named Patient Access of orBec® in Europe
[read more]Monday, June 30, 2008
DOR BioPharma Announces Collaboration with Numoda Corporation for the Execution of Confirmatory, Phase 3 Clinical Trial of orBec®
[read more]Friday, May 23, 2008
DOR BioPharma Opens New Corporate Office in United Kingdom
[read more]Thursday, May 22, 2008
DOR BioPharma Provides Update on orBec® European Regulatory and Development Strategy, DOR Enters into Letter of Intent with IDIS for Named Patient Access of orBec® in Europe
[read more]Friday, May 16, 2008
DOR BioPharma Reports 1st Quarter 2008 Financial Results
[read more]Friday, May 09, 2008
DOR BioPharma Announces Appointment of Christopher J. Schaber, PhD, to Board of Directors of the Alliance for Biosecurity
[read more]Thursday, May 08, 2008
DOR BioPharma Acquires Option for Third-Generation Anthrax Vaccine from Harvard University
[read more]Tuesday, April 29, 2008
DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVax™, its Vaccine Against Ricin Toxin
[read more]Thursday, March 27, 2008
DOR BioPharma Reports Year-End 2007 Financial Results
[read more]Friday, February 15, 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in South Korea in Collaboration with BL&H Co., Ltd.
[read more]Thursday, February 14, 2008
DOR BioPharma Enters Into $8.5 Million Common Stock Purchase Agreement
[read more]Wednesday, February 13, 2008
DOR BioPharma Announces Positive New Pulmonary Effect Data from orBec® Clinical Trials, Abstract and Results to be Presented Today at Annual Tandem Bone Marrow Transplant Conference in San Diego
[read more]Tuesday, January 29, 2008
DOR BioPharma Reports Achievement of Two-Year Stability Milestone for RiVax™, its Vaccine Against Ricin Toxin
[read more]Thursday, January 03, 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease, Treatment Could Benefit Approximately 100,000 Pediatric Patients in the US Afflicted with Crohn's Disease
[read more]Tuesday, January 01, 2008
To obtain prior news releases, please contact the company at (609) 538-8200.
